<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://compepharma.com/story/n-32cdc83302adad7f79e1</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Health Canada lists Class II recall of Stryker&#x27;s Blueprint shoulder-planning software over two bugs</news:title></news:news></url><url><loc>https://compepharma.com/story/n-b900a624e3076f45636c</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports</news:title></news:news></url><url><loc>https://compepharma.com/story/n-4e319938ba4a21570f4e</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Health Canada: Raz Design recalls shower commode chairs over seats that can break</news:title></news:news></url><url><loc>https://compepharma.com/story/c-af2c9505abc693eefd93</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>CMS moves Alimetry&#x27;s Gastric Alimetry test to higher Medicare outpatient payment tier for 2027</news:title></news:news></url><url><loc>https://compepharma.com/story/c-ffc55cda3c41e622ce7d</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises</news:title></news:news></url><url><loc>https://compepharma.com/story/c-7d6f7a562fb982938949</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC</news:title></news:news></url><url><loc>https://compepharma.com/story/c-befca81e4b86e05ab8c1</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform</news:title></news:news></url><url><loc>https://compepharma.com/story/c-18ca2a6aa95bc4e95091</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma</news:title></news:news></url><url><loc>https://compepharma.com/story/c-27671f4a22ae3d7d59ee</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path</news:title></news:news></url><url><loc>https://compepharma.com/story/c-61108086bf67f9b210e9</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns</news:title></news:news></url><url><loc>https://compepharma.com/story/c-aa103861558c86af26d7</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed</news:title></news:news></url><url><loc>https://compepharma.com/story/c-659d7e72ea0b3db3093e</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned</news:title></news:news></url><url><loc>https://compepharma.com/story/c-72541949943ca65c87ca</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial</news:title></news:news></url><url><loc>https://compepharma.com/story/c-a5ac5190ca80fe656df2</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop</news:title></news:news></url><url><loc>https://compepharma.com/story/c-8ec055ab42a83d54ce95</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma</news:title></news:news></url><url><loc>https://compepharma.com/story/c-72a975f5aef6d839c386</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth</news:title></news:news></url><url><loc>https://compepharma.com/story/c-399d7c55a6c957a09334</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer</news:title></news:news></url><url><loc>https://compepharma.com/story/c-444f5c177ece5ac1881a</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer</news:title></news:news></url><url><loc>https://compepharma.com/story/c-3563ae5ee73281185684</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>MAIA reports 88% disease control for ateganosine-cemiplimab in third-line NSCLC</news:title></news:news></url><url><loc>https://compepharma.com/story/c-e7d4b363b1d0dbfa7588</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Allarity extends Phase 2 stenoparib ovarian cancer trial to platinum-refractory and non-RECIST patients</news:title></news:news></url><url><loc>https://compepharma.com/story/c-e14dbbc81716ffffc9b6</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>OXB confirms manufacturing deal with Aura Biosciences for bel-sar Phase 3 and commercial supply</news:title></news:news></url><url><loc>https://compepharma.com/story/c-a209e23e22ad27b16a5f</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Zentek reports C$15.2M six-month profit on impairment reversal; cash rises to C$13.6M</news:title></news:news></url><url><loc>https://compepharma.com/story/c-df13d1a24e5ca4d50705</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>UL Solutions to acquire supply chain software firm Worldly in roughly $350M deal</news:title></news:news></url><url><loc>https://compepharma.com/story/c-3b6c2fb8303f5bc6cb8a</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Vivos Therapeutics regains Nasdaq equity compliance as Q3 revenue rises 24% sequentially</news:title></news:news></url><url><loc>https://compepharma.com/story/c-9413b4faeb38ab58d2e1</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>NeOnc says NEO100 met Phase 2a endpoint in recurrent IDH1-mutant glioma, but criteria diverge</news:title></news:news></url><url><loc>https://compepharma.com/story/c-08d4587df06c2869c73c</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Mesoblast reports US$115M first full-year Ryoncil sales and advances four late-stage programmes</news:title></news:news></url><url><loc>https://compepharma.com/story/c-1fb366ae65a9f052eb3f</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA approves Novartis&#x27; Cosentyx 150 mg for polymyalgia rheumatica</news:title></news:news></url><url><loc>https://compepharma.com/story/o-d1ef32c47d53b651</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Diagnostica Stago recalls lot of STHEMO DDi M, Dutch inspectorate notice shows</news:title></news:news></url><url><loc>https://compepharma.com/story/o-2d57947efffd2dbd</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>MHRA lists eight device Field Safety Notices in weekly update for 9–13 November</news:title></news:news></url><url><loc>https://compepharma.com/story/o-0fea7ce39f91c8b9</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>AEMPS veterinary committees note 21 pharmacovigilance-driven authorisation changes and recall follow-up problems</news:title></news:news></url><url><loc>https://compepharma.com/story/o-8872ab28e3df0141</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA classes Cardinal Health Presource kit correction as Class I over recalled BD Alaris infusion sets</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-19-retension-s-51-75m-ipo-buys-a-phase-2b-readout-but-trial-costs-will-set-the-cloc</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Retension&#x27;s $51.75M IPO buys a Phase 2b readout, but trial costs will set the clock</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-19-view-reimbursement-not-approval-is-the-commercial-gate-and-leaders-should-plan-accord</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Reimbursement, not approval, is the commercial gate, and leaders should plan accordingly</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-19-insight-molecular-s-15m-raise-shows-how-thin-the-small-cap-diagnostics-funding-m</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Insight Molecular&#x27;s $15M raise shows how thin the small-cap diagnostics funding market is</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-19-tonix-s-tonmya-reaches-15m-but-a-163m-cash-pile-and-a-paragraph-iv-filing-frame</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19</news:publication_date><news:title>Tonix&#x27;s TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-view-show-your-working-launch-revenue-is-the-lagging-indicator-and-this-season-proves</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Show your working: launch revenue is the lagging indicator, and this season proves it</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-adc-therapeutics-volume-led-sales-and-deeper-cost-cuts-as-recapitalisation-shift</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-kyntra-s-prostate-exit-shows-how-thin-the-funding-runway-is-for-a-biotech-that-h</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Kyntra&#x27;s prostate exit shows how thin the funding runway is for a biotech that has to reset</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-view-gross-margin-is-the-number-that-turns-a-launch-into-a-business</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Gross margin is the number that turns a launch into a business</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-protagenic-s-5m-placement-shows-the-gap-between-windward-s-ipo-and-microcap-fund</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Protagenic&#x27;s $5M Placement Shows the Gap Between Windward&#x27;s IPO and Microcap Funding</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-inhibrx-s-q3-debt-and-launch-prep-push-losses-up-as-chondrosarcoma-review-looms</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Inhibrx&#x27;s Q3: Debt and launch prep push losses up as chondrosarcoma review looms</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-jasper-s-igan-readout-nears-as-small-cap-biotechs-fund-through-deals-and-sales</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Jasper&#x27;s IgAN readout nears as small-cap biotechs fund through deals and sales</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-view-the-first-launch-is-a-down-payment-this-earnings-season-rewards-the-label-that-f</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>The first launch is a down payment: this earnings season rewards the label that funds the next one</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-viatris-closes-pacira-buy-taking-its-pain-bet-live-as-mid-cap-deal-flow-builds</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Viatris closes Pacira buy, taking its pain bet live as mid-cap deal flow builds</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-18-talphera-s-q3-no-revenue-a-smaller-per-share-loss-and-an-fda-bet-on-early-nephro</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18</news:publication_date><news:title>Talphera&#x27;s Q3: no revenue, a smaller per-share loss and an FDA bet on early NEPHRO enrollment close</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-view-self-funding-is-the-milestone-small-cap-pharma-should-be-chasing-this-earnings-s</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Self-funding is the milestone small-cap pharma should be chasing this earnings season</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-liquidia-s-yutrepia-hits-222-7m-in-q3-as-a-389-7m-settlement-charge-clears-the-c</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Liquidia&#x27;s YUTREPIA hits $222.7M in Q3 as a $389.7M settlement charge clears the courtroom</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-ul-solutions-350m-worldly-deal-shows-data-and-compliance-assets-joining-the-deal</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>UL Solutions&#x27; $350M Worldly Deal Shows Data and Compliance Assets Joining the Dealmaking Mix</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-view-launches-are-won-in-the-plumbing-and-this-earnings-season-shows-it</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Launches are won in the plumbing, and this earnings season shows it</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-endra-s-pending-noble-africa-merger-shows-small-cap-deal-fatigue-on-a-crowded-m</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>ENDRA&#x27;s Pending Noble Africa Merger Shows Small-Cap Deal Fatigue on a Crowded M&amp;A Day</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-harrow-s-record-q3-revenue-meets-a-halved-ebitda-outlook-as-q4-must-carry-the-ye</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Harrow&#x27;s record Q3 revenue meets a halved EBITDA outlook, as Q4 must carry the year</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-merck-kgaa-s-0-75-a-share-rapid-micro-bid-caps-a-day-of-small-cap-pharma-consoli</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Merck KGaA&#x27;s $0.75-a-share Rapid Micro bid caps a day of small-cap pharma consolidation</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-view-cadence-is-the-asset-quarters-that-compound-are-worth-more-than-quarters-that-sp</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Cadence is the asset: quarters that compound are worth more than quarters that spike</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-rosemont-s-56m-aytu-bid-shows-buyers-paying-for-growing-launches-not-pipelines</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Rosemont&#x27;s $56M Aytu bid shows buyers paying for growing launches, not pipelines</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-cormedix-q3-post-tdapa-defencath-reset-meets-heron-deal-and-a-suspended-2027-out</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook</news:title></news:news></url></urlset>